An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 26, 2016

Primary Completion Date

March 16, 2017

Study Completion Date

March 16, 2017

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Exenatide

Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)

DRUG

Albiglutide

Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning

Trial Locations (2)

40213

GSK Investigational Site, Louisville

75230

GSK Investigational Site, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Wake Forrest Baptist Health

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT02793154 - An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects | Biotech Hunter | Biotech Hunter